Zomedica Corp. [AMEX: ZOM] price plunged by -2.56 percent to reach at -$0.02. The company report on October 21, 2021 that SPAR Group Elects Mr. Sean M. Whelan and Mr. Michael Wager to its Board of Directors.
The SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR Group”) board of directors (the Board”) has elected Sean M. Whelan and Michael Wager to the Board, effective October 14, 2021.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Mr. Sean M. Whelan is currently the Chief Executive Officer, and was previously the Chief Financial Officer, for Encore Rehabilitation Services. Mr. Whelan has also held the Chief Financial Officer role for several other public and private companies including Smile America Partners, Bedrock Manufacturing, LLC, Diplomat Pharmacy and InfuSystem Holdings, Inc. Mr. Whelan is currently a Board member and Chairman of the Audit Committee with Zomedica Corp (NYSE American: ZOM) and also a Board member with OptioRx; he previously served as an Executive Board member with Diplomat Pharmacy and InfuSystem Holdings, Inc. Mr. Whelan earned his Bachelor of Business Administration Degree and his Master of Accounting Degree at the University of Michigan’s Ross School of Business and is a CPA.
A sum of 20577387 shares traded at recent session while its average daily volume was at 26.43M shares. Zomedica Corp. shares reached a high of $0.52 and dropped to a low of $0.50 until finishing in the latest session at $0.51.
The average equity rating for ZOM stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Zomedica Corp. [ZOM]:
The Average True Range (ATR) for Zomedica Corp. is set at 0.03, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 17275.87. The Price to Book ratio for the last quarter was 1.84, with the Price to Cash per share for the same quarter was set at 0.28.
ZOM Stock Performance Analysis:
Zomedica Corp. [ZOM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.90. With this latest performance, ZOM shares dropped by -4.26% in over the last four-week period, additionally sinking by -52.35% over the last 6 months – not to mention a rise of 598.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 47.97, with the RSI for the last a single of trading hit 49.71, and the three-weeks RSI is set at 46.69 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.5366, while it was recorded at 0.5124 for the last single week of trading, and 1.0120 for the last 200 days.
Insight into Zomedica Corp. Fundamentals:
Return on Total Capital for ZOM is now -50.05, given the latest momentum, and Return on Invested Capital for the company is -51.08. Return on Equity for this stock declined to -51.94, with Return on Assets sitting at -48.09. When it comes to the capital structure of this company, Zomedica Corp. [ZOM] has a Total Debt to Total Equity ratio set at 2.96. Additionally, ZOM Total Debt to Total Capital is recorded at 2.88, with Total Debt to Total Assets ending up at 2.82. Long-Term Debt to Equity for the company is recorded at 2.13, with the Long-Term Debt to Total Capital now at 1.68.
Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 81.40 and a Current Ratio set at 81.70.
Zomedica Corp. [ZOM] Insider Position Details
There are presently around $67 million, or 15.60% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 42,501,241, which is approximately 4.231% of the company’s market cap and around 0.10% of the total institutional ownership; STATE STREET CORP, holding 18,366,408 shares of the stock with an approximate value of $9.46 million in ZOM stocks shares; and BLACKROCK INC., currently with $8.92 million in ZOM stock with ownership of nearly 0.899% of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 55 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 40,359,146 shares. Additionally, 42 investors decreased positions by around 10,928,011 shares, while 34 investors held positions by with 79,638,441 shares. The mentioned changes placed institutional holdings at 130,925,598 shares, according to the latest SEC report filing. ZOM stock had 30 new institutional investments in for a total of 19,378,906 shares, while 26 institutional investors sold positions of 8,415,094 shares during the same period.